UNSPSC 51112610: Nimustine hydrochloride

This classification denotes a nitrosourea compound with the molecular formula C9H13ClN6O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DFR965WKBU, chemically known as urea, n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(2-chloroethyl)-n-nitroso- but more generally known as nimustine hydrochloride, which bears US NIH Compound Identifier 39214. European Medicines Agency schedules Nimustine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03435MIG.

UNSPSC 51112610 Nimustine hydrochloride is a Commodity code covering a specific oncology pharmaceutical agent. State and local governments procure this drug primarily through health and human services agencies managing pharmacy benefits and cancer treatment programs for eligible populations, including state employees, Medicaid beneficiaries, and public hospital patients. The work under this code involves securing supply channels, negotiating pricing and rebate structures, and managing distribution to authorized dispensing facilities. Issuing bodies are predominantly state health and human services departments and related pharmacy benefit management entities that administer drug formularies and procurement on behalf of public health systems.

Texas Health and Human Services Commission posted Request for Information (RFI) No. HHS0017013 on April 3, 2026, seeking vendor capabilities regarding direct-to-manufacturer prescription programs as an alternative to traditional pharmacy benefit manager and group purchasing organization channels. The RFI solicits information from vendors about their experience with direct contracting for self-insured employers and health plans, flexibility to negotiate net pricing models without rebates, and capacity to implement value-based agreements. This RFI represents preliminary market intelligence gathering by the state before issuing a formal Request for Proposal. No award values, budget ranges, set-aside designations, or specific response deadlines beyond the information deadline are identified in this stage. Recent procurement activity under the code appears limited to this single Texas initiative; no other state or local opportunities are currently visible in the market.